Schrödinger outlines 2026 ACV of $222M-$232M while raising drug discovery revenue to $75M-$85M
FROM THE WIRE · SEEKINGALPHA.COM
Earnings Call Insights: Schrödinger (SDGR) Q3 2026 MANAGEMENT VIEW * "Our third quarter results reflect sustained commercial momentum and strong progress towards the long-range goals we outlined earlier this year." (CEO, President & Director Ramy Farid) * "ACV grew 17% or 24%…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishRaised full-year guidance for ACV and drug discovery revenue is a positive signal for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01According to the CEO, ACV grew 17%, or 24% excluding contribution ACV.
- 02Full-year guidance was raised for both ACV and drug discovery revenue.
- 03Bunsen, an Agentic AI platform, now handles about 80% of high throughput calculations.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets